HRTX · NASDAQ
Heron Therapeutics, Inc.
$0.30 +0.01 (+2.23%)
Company overview
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer…
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $57M
- Employees
- 122
- Headquarters
- Cary, CA
- Website
- herontx.com
- CEO
- Craig Alexander Collard
- Listed
- August 26, 1987
- P/E
- -1.69
- Dividend yield
- 0.00%
Company financials
- Revenue
- $151M
- Gross profit
- $107M
- Operating income
- -$10.5M
- EBITDA
- -$20.6M
- Net income
- -$30.9M
- EPS
- -$0.18
- Total assets
- $246M
- Total debt
- $142M
- Gross margin
- 71.12%
- Net margin
- -20.53%
- Earnings yield
- -59.07%
No geographic segmentation.
Showing FY 2025
HRTX
1D
NASDAQ
O0.29H0.30L0.28C0.30-0.00 (-0.66%)Vol257.07K